Table 3 Anti-tumor nanomedicines in clinical trials
From: Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Therapeutic type | Product name | Therapeutic agent | Nanocarrier | Administration route | Indications | Trial No. | Stage |
|---|---|---|---|---|---|---|---|
Chemotherapy | ThermoDox | Doxorubicin | Liposome | iv. | Liver cancer | NCT02181075 | Phase 1 |
Chemotherapy | LEP-ETU | Paclitaxel | Liposome | iv. | Neoplasm | NCT00080418 | Phase 1 |
Chemotherapy | Nano-QUT | Quercetin | PLGA-PEG NPs | iv. | Oral cancer | NCT05456022 | Phase 2 |
Chemotherapy | NK 105 | Paclitaxel | Micellar nanoparticle | iv. | Breast cancer | NCT01644890 | Phase 3 |
Chemotherapy | Docetaxel-PM | Docetaxel | polymeric micelle | iv. | Esophagus squamous cell carcinoma, metastatic cancer | NCT03585673 | Phase 2 |
Chemotherapy | BIND-014 | Docetaxel | Polymeric micelles | iv. | KRAS positive non-small cell lung cancer, squamous cell non-small cell lung cancer | NCT02283320 | Phase 2 |
Chemotherapy | Genexol PM | Paclitaxel | Polymeric micelles | iv. | Bladder cancer, ureter cancer | NCT01426126 | Phase 2 |
Chemotherapy | Nab-paclitaxel (Abraxane) | Paclitaxel | Albumin | iv. | Non-small cell lung cancer | NCT02016209 | Phase 2 |
Chemotherapy | Abraxane | Paclitaxel | Albumin | iv. | Pancreatic cancer | NCT00691054 | Phase 2 |
Chemotherapy | NC-6004 | Cetuximab | polymeric micelle | iv. | Head and neck neoplasms | NCT02817113 | Phase 1 |
Chemotherapy | MBP-426 | Oxaliplatin | Liposome | iv. | cancer | NCT00355888 | Phase 1 |
Chemotherapy | FF-10850 | Topotecan | Liposomes | iv. | Advanced solid tumors | NCT04047251 | Phase 1 |
Chemotherapy | Cetuximab nanoparticles | Cetuximab | Ethylcellulose nanoparticles | iv. | Colon cancer | NCT03774680 | Phase 1 |
Chemotherapy | Docetaxel-PNP | Docetaxel | Liposome | iv. | Advanced solid malignancies | NCT01103791 | Phase 1 |
Chemotherapy | ABT-888 | Doxorubicin | PEGylated liposomes | iv. | Ovarian cancer | NCT01113957 | Phase 2 |
Chemotherapy | CPX-351 | Cytarabine and daunorubicin at 5:1 ratio | Liposomes | iv. | Acute myeloid leukemia | NCT02286726 | Phase 2 |
Chemotherapy | LipoVNB | Vinorelbine tartrate | Liposomes | iv. | Advanced malignancy | NCT02925000 | Phase 1/2 |
Chemotherapy | CriPec | Docetaxel | Polymeric micelles | iv. | Ovarian cancer | NCT03742713 | Phase 2 |
Chemotherapy | LY01610 | Irinotecan hydrochloride | Liposomes | iv. | Small cell lung cancer | NCT04381910 | Phase 2 |
Chemotherapy | Liposome doxorubicin | Doxorubicin | Liposomes | iv. | Desmoid tumor | NCT05561036 | Phase 3 |
Chemotherapy | EndoTAG-1 | Paclitaxel | Cationic liposomes | iv. | Breast cancer | NCT01537536 | Phase 2 |
Chemotherapy | KM1 | Carboplatin | Virus | iv. | Ovarian cancer | NCT05684731 | Phase 1 |
Immunotherapy | mRNA-NP vaccine | Autologous total tumor mRNA | Liposome | iv. | Melanoma | NCT05264974 | Phase 1 |
Immunotherapy | Dex2 | Antigen | Exosome | iv. | Non-small cell lung cancer | NCT01159288 | Phase 2 |
Radiotherapy | AGuIX-NP | Cisplatin | Inorganic NPs | — | Gynecologic cancer | NCT03308604 | Phase 1 |
Radiotherapy | AGuIX-NP | Temozolomide | Inorganic NPs | — | Glioblastoma | NCT04881032 | Phase 1/2 |
Radiotherapy | NBTXR3 | — | Hafnium Oxide NPs | it. | Advanced and/or metastatic malignant solid neoplasm, metastatic malignant liver cancer, metastatic malignant lung cancer | NCT05039632 | Phase 1/2 |
Gene therapy | iExosomes | KRAS G12D siRNA | Exosomes | iv. | Metastatic pancreas cancer | NCT03608631 | Phase 1 |
